Susquehanna International Group
BOLT icon

Susquehanna International Group’s Bolt Biotherapeutics BOLT Stock Holding History

Susquehanna International Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,657
Closed -$47.1K – 13414
2026
Q1 		$47.1K Buy
+11,657
New +$60.7K ﹤0.01% 12650
2025
Q4 		– Sell
-16,642
Closed -$88.5K – 12389
2025
Q3 		$88.5K Buy
+16,642
New +$92.3K ﹤0.01% 11640
2025
Q2 		– Sell
-1,087
Closed -$8.69K – 12689
2025
Q1 		$8.69K Buy
+1,087
New +$10.4K ﹤0.01% 12224
2024
Q4 		– Sell
-7,396
Closed -$95.9K – 12212
2024
Q3 		$95.9K Buy
7,396
+6,275
+560% +$86.5K ﹤0.01% 11076
2024
Q2 		$16.8K Buy
+1,121
New +$22.1K ﹤0.01% 11700
2023
Q2 		– Sell
-1,006
Closed -$28K – 12094
2023
Q1 		$28K Sell
1,006
-9
-0.9% -$263 ﹤0.01% 11943
2022
Q4 		$26.4K Buy
+1,015
New +$27.8K ﹤0.01% 11667
2022
Q3 		– Sell
-877
Closed -$36K – 13180
2022
Q2 		$36K Buy
+877
New +$34K ﹤0.01% 12141

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group's BOLT Position: Q2 2026 in Review

Susquehanna International Group sold out of Bolt Biotherapeutics (BOLT) in Q2 2026, closing a stake of 11,657 shares — an estimated $47.1K sold.

Susquehanna International Group first reported a position in BOLT in Q2 2022 and held it in 8 quarters. The position peaked at $95.9K in Q3 2024. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Susquehanna International Group reported no remaining Bolt Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Susquehanna International Group sold 11,657 Bolt Biotherapeutics shares in Q2 2026, an estimated $47.1K.
  • Susquehanna International Group first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 8 quarters.
  • Susquehanna International Group's Bolt Biotherapeutics position peaked at $95.9K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.